Cargando…

Health Tract, No. 177: Cancer

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	1863
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190915/ https://www.ncbi.nlm.nih.gov/pubmed/36486893

Ejemplares similares

Health Tract, No. 177: Cancer
Publicado: (1865)

Inter-comparison of quantitative imaging of lutetium-177 ((177)Lu) in European hospitals
por: Wevrett, Jill, et al.
Publicado: (2018)

Subject index for volume 177
Publicado: (1990)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Evaluation of the (177m)Lu-concentration in in-house produced (177)Lu-radiopharmaceuticals and commercially available Lutathera(®)
por: Balzer, Matthias, et al.
Publicado: (2023)

Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats
por: Yousefnia, Hassan, et al.
Publicado: (2015)

Heterogeneity of Human Neutrophil CD177 Expression Results from CD177P1 Pseudogene Conversion
por: Wu, Zuopeng, et al.
Publicado: (2016)

Remarks on 177 Operations for Entropium and Trichiasis
por: Hotz, F. C.
Publicado: (1883)

Neutron resonance parameters of $^{177}$Hf
por: Georgiev, G, et al.
Publicado: (1996)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Radionuclide generator-based production of therapeutic (177)Lu from its long-lived isomer (177m)Lu
por: Bhardwaj, Rupali, et al.
Publicado: (2019)

Esophageal cancer statistics in China, 2011: Estimates based on 177 cancer registries
por: Zeng, Hongmei, et al.
Publicado: (2015)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
por: Gadot, Moran, et al.
Publicado: (2020)

A measurement of the branching ratios for the decays D<sup>±</sup><sub>S</sub> -> K<sup>0</sup> K<sup>±</sup> and D<sup>±</sup><sub>S</sub> -> K<sup>*±</sup> K<sup>0</sup>
por: Giehl, I
Publicado: (1995)

Development of (177)Lu-phytate Complex for Radiosynovectomy
por: Yousefnia, Hassan, et al.
Publicado: (2013)

Increase expression of CD177 in Kawasaki disease
por: Huang, Ying-Hsien, et al.
Publicado: (2019)

Radiosynovectomy of the elbow joint synovitis in rheumatoid arthritis treated with Lutetium - 177 labeled hydroxylapatite (Lu-177 HA) particulates; first case report and image of Lu -177 HA in the elbow joint
por: Kamaleshwaran, Koramadai Karuppusamy, et al.
Publicado: (2014)

Factors Predictive of Subretinal Fluid Resolution in Coats Disease: Analysis of 177 Eyes in 177 Patients at a Single Center
por: Khoo, Chloe T.L., et al.
Publicado: (2019)

(177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Sanli, Yasemin, et al.
Publicado: (2021)

General treatment for metastatic colorectal cancer: From KEYNOTE 177 study
por: Ding, Yuwei, et al.
Publicado: (2021)

ALLN-177, oral enzyme therapy for hyperoxaluria
por: Lingeman, James E., et al.
Publicado: (2019)

Challenges and future options for the production of lutetium-177
por: Vogel, W. V., et al.
Publicado: (2021)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

IAU Symposium 177 : the Carbon Star Phenomenon
Publicado: (1996)

Memorandum: extension of the collaboration of experiment PS 177
por: Polikanov, S M
Publicado: (1981)

Minutes of the 177th Meeting of the Research Board
por: CERN. Geneva. Research Board
Publicado: (2006)

CD177 Expression and Inflammation Grade in Helicobacter pylori-Infected Wild-Type and CD177(−/−) C57BL/6 Mice
por: Yang, Xing-Tang, et al.
Publicado: (2019)

Cancer cell-intrinsic function of CD177 in attenuating β-Catenin signaling
por: Kluz, Paige N., et al.
Publicado: (2020)

Inhibition of Wntless/GPR177 suppresses gastric tumorigenesis
por: Seo, Jaesung, et al.
Publicado: (2018)

Preparation and evaluation of Lu-(177) phytate Complex for Radiosynovectomy
por: Yousefnia, Hassan, et al.
Publicado: (2014)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016)

Frequency of Ambiguous Genitalia in 14,177 Newborns in Turkey
por: Aydin, Banu Kucukemre, et al.
Publicado: (2019)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using (177)Lu-iPSMA and (177)Lu-DOTATOC: Experience after 905 Treatment Doses
por: Luna-Gutiérrez, Myrna, et al.
Publicado: (2023)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

AB177. Clinical and pathological research of prostate cancer with Gleason score 10
por: Yan, Bin, et al.
Publicado: (2016)

(177)Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment
por: Bergmann, Ralf, et al.
Publicado: (2016)

Lutetium-177-PSMA-617: A Vision of the Future
por: Chandran, Elias, et al.
Publicado: (2022)

Lutetium Lu 177 Vipivotide Tetraxetan: First Approval
por: Keam, Susan J.
Publicado: (2022)

Developments in (177)Lu-based radiopharmaceutical therapy and dosimetry
por: George, Siju C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kt089ehf6r3a2gvsjkja2en6le